Groundbreaking study explores prenatal drug therapy for osteogenesis imperfecta

Shriners Children's St. Louis is proud to announce that one of its lead researchers, Dr. Arin Oestreich, has been awarded a $3.1 million R01 grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The funding will support Dr. Oestreich's groundbreaking work exploring how targeted therapy for rare bone diseases, such as osteogenesis imperfecta (OI), given to babies still in the womb can improve their condition.

An estimated 50,000 people in the United States currently have osteogenesis imperfecta, an inherited condition that causes bones to be extremely fragile and prone to fracture. Over the next five years, Dr. Oestreich will collaborate with Dr. Laura Schulz and Dr. Charlotte Phillips while working across campuses at Washington University in St. Louis, the University of Missouri, and Shriners Children's St. Louis. Together, they aim to develop a prenatal drug therapy that strengthens bone formation before birth, potentially improving outcomes for both the mother and child.

This study explores therapeutic strategies to block myostatin, a protein that normally slows muscle growth. When myostatin is blocked, muscles and bones grow larger. Currently in the pre-clinical phase, a mouse model is used to see preliminary data such as litter size, pregnancy rate, outcomes, and pup growth. One of the study's key focus points is identifying critical developmental windows during which early therapeutic intervention can set the stage to achieve peak bone mass of the fetus, and the impact it has across the entire lifespan.

This pioneering research emphasizes Shriners Children's St. Louis's commitment to advancing life-changing pediatric care through scientific discovery and collaboration.

"But it's not just a pediatric disease," said Dr. Oestreich. "We're also thinking about the mother's bone strength and how these strategies could support her. Pregnancy and lactation put significant stress on the body and skeleton, so we're exploring whether this approach can also help mothers with OI maintain their bone strength during these time points."

The team recently released their first publication in this area, showing that blocking myostatin in female mice with OI from before pregnancy until the end of lactation increased maternal muscle mass and cortical bone size. These results suggest that myostatin inhibition could specifically reduce pregnancy and lactation‑related bone loss and improve bone quality in mothers with brittle bone disease.

Source:

Shriners Hospitals for Children

Journal reference: